What is Eris Lifesciences Ltd (ERIS) share price return in the past 10 years?

Data is not available for this company

What is the share price of Eris Lifesciences Ltd (ERIS)?

Company share prices are keep on changing according to the market conditions. The current trading price of Eris Lifesciences Ltd (ERIS) on 24-Jun-2026 16:59:59 at 16:59 is 1465.45.

What is the P/E ratio of Eris Lifesciences?

The latest standalone P/E ratio of Eris Lifesciences as of 24-Jun-2026 is 83.21.

What is the P/B ratio of Eris Lifesciences Ltd (ERIS)?

The latest standalone P/B ratio of Eris Lifesciences Ltd (ERIS) as of 24-Jun-2026 is 6.35.

What is the 52-week high and low of Eris Lifesciences Ltd (ERIS)?

The 52-week high of Eris Lifesciences Ltd (ERIS) is Rs. 1887.65 and the 52-week low is Rs. 1237.90.

Eris Lifesciences Ltd (ERIS) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Eris Lifesciences Ltd (ERIS)
Brand: Eris Lifesciences

Key Metrics

Valuation Multiples

Market Cap

₹20,306 Cr.

Current Price

₹1,465.5

52-Week Low / High

₹1,238 / 1,888

TTM EPS

₹44.7

TTM Sales

₹3,115 Cr.

Book Value per Share

₹281.6

P/E Ratio

32.78

Higher than its 5-year historical median

Industry PE

48.5

Price to Book (P/B)

5.20

In line with its 5-year historical median

Price to Sales (P/S)

6.52

Lower than its 5-year historical median

EV/EBITDA

19.99

In line with its 5-year historical median

Dividend Yield

0.5%

Profitability Efficiency

Return on Equity (ROE)

13.81%

Outperforms industry median

Return on Capital Employed (ROCE)

13.59%

Outperforms industry median

Return on Assets (ROA)

5.48%

Operating Profit Margin

35.2%

Net Profit Margin

12.95%

Gross Profit Margin

27.1%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

44.02%

Operating Profit Growth (1 Year)

Improving versus 3-year growth rate

50.73%

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

-5.65%

Asset Quality

Promoter Holding

53.92%

Pledged shares (%) of Promoter's holding (%)

16.92%

Reserves

₹3,889 Cr.

Equity

₹13.9 Cr.

Face Value

₹1

All Time Low / High

₹341.05 / 1909.55

Eris Lifesciences stock performance

Key Ratios

Check Before You Invest

Quality

Locked

Valuation

Locked

Price Trend

Locked

Q.1 Is Eris Lifesciences Ltd a good quality company?

Eris Lifesciences Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Eris Lifesciences Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Eris Lifesciences Ltd vs industry peers?

Eris Lifesciences Ltd revenue CAGR is 21.92%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Eris Lifesciences Ltd?

Promoters hold 53.92% of the Eris Lifesciences Ltd, with 16.92% of their stake pledged, indicating high pledge risk.

Q.1 Stock return of Eris Lifesciences Ltd over the last decade?

Over the last 5 year(s), the stock has delivered a CAGR of 14% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	54.6%	62.6%	35.8%	26.5%	25.4%	27.6%	25.3%	17.3%	12.4%	13.6%	-
Value Creation Index ⓘ	3.9	3.5	1.7	1.0	0.9	1.0	0.9	0.3	-0.1	0.0	-
Growth Parameters ⓘ
Sales ⓘ	597	750	856	982	1,074	1,212	1,347	1,685	2,009	2,894	3,115
Sales YoY Gr.	-	25.5%	14.2%	14.8%	9.4%	12.8%	11.2%	25.1%	19.2%	44%	-
Adj EPS ⓘ	9.6	16.7	20.2	21	21.6	26	30	27.8	28.6	25.7	44.7
YoY Gr.	-	74.8%	20.5%	4.3%	2.7%	20.5%	15.3%	-7.1%	2.6%	-9.9%	-
BVPS (₹) ⓘ	21.7	41.3	62.6	83.6	95.3	115.8	140.3	161.3	189.8	208.8	281.6
Adj Net Profit ⓘ	132	230	277	289	293	353	408	379	388	350	620
Cash Flow from Ops. ⓘ	131	200	235	223	271	375	378	292	486	1,065	-
Debt/CF from Ops. ⓘ	0	0	1.6	0.8	0	0	0.1	2.9	5.6	2.3	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	19.2%	21.9%	29%	44%
Adj EPS ⓘ	11.6%	3.6%	-5%	-9.9%
BVPSⓘ	28.6%	17%	14.2%	10%
Share Price	-	16.1%	30.2%	-9.9%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	46.5	53.1	38.8	28.7	24	24.6	23.4	18.5	16.2	12.9	18.2
Op. Profit Mgn % ⓘ	28.8	35.9	37.7	35.2	34.7	35.6	36.3	32	33.7	35.2	36
Net Profit Mgn % ⓘ	22.3	30.7	32.5	29.5	27.3	29.1	30.2	22	19.6	12.9	19.9
Debt to Equity ⓘ	0	0	0.4	0.2	0	0	0	0.4	1.1	0.9	0.2
Working Cap Days ⓘ	68	77	101	118	130	136	145	143	159	138	86
Cash Conv. Cycle ⓘ	12	11	-4	-4	7	14	13	29	37	34	-20

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	597	749	856	982	1,074	1,212	1,347	1,685	2,009	2,894
Operating Expenses ⓘ +	425	480	533	637	706	781	862	1,148	1,334	1,876
Manufacturing Costs	11	8	8	11	19	15	43	21	36	60
Material Costs	98	134	142	154	172	238	259	352	380	714
Employee Cost	125	131	157	191	206	229	250	346	404	505
Other Costs ⓘ	191	207	227	281	310	298	310	429	515	597
Operating Profit ⓘ	172	269	322	345	368	431	485	537	675	1,017
Operating Profit Margin (%)	28.8%	35.9%	37.6%	35.1%	34.3%	35.5%	36.0%	31.9%	33.6%	35.2%
Other Income ⓘ +	3	25	26	32	16	9	26	11	24	18
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0	1	11	23	2	2	4	26	85	231
Depreciation ⓘ	20	23	26	36	50	43	65	117	183	315
Profit Before Tax ⓘ	154	270	312	317	331	394	442	405	431	489
Tax ⓘ	20	24	17	26	35	39	36	30	34	114
Profit After Tax	135	247	295	291	297	355	406	374	397	375
PAT Margin (%)	22.6%	32.9%	34.5%	29.6%	27.6%	29.3%	30.1%	22.2%	19.8%	13.0%
Adjusted EPS (₹)	9.7	18.0	21.4	21.2	21.8	26.2	29.9	28.1	28.8	25.8
Dividend Payout Ratio (%)	62.40%	0%	0%	0%	13.10%	21%	20.10%	26.20%	0%	28.50%

Valuation of Eris Lifesciences - Consolidated

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	300	567	861	1,149	1,293	1,572	1,906	2,193	2,581	2,844
Share Capital ⓘ	0	14	14	14	14	14	14	14	14	14
Reserves ⓘ	299	553	848	1,136	1,280	1,559	1,893	2,180	2,568	2,831
Debt +	0	0	274	0	0	0	45	699	1,966	2,134
Long Term Debt	0	0	274	0	0	0	45	644	655	1,738
Short Term Debt	0	0	0	0	0	0	0	55	1,311	397
Minority Interest	3	24	25	18	0	0	-0	25	636	417
Trade Payables	25	39	91	84	100	103	118	125	219	332
Others Liabilities ⓘ	64	102	177	229	43	28	44	430	1,409	1,134
Total Liabilities ⓘ	392	732	1,428	1,481	1,437	1,703	2,113	3,472	6,810	6,862
Fixed Assets
Net Fixed Assets ⓘ +	71	232	771	761	875	854	918	2,568	4,319	5,306
Gross Block	123	254	820	838	984	1,006	1,092	2,843	4,773	6,061
Accumulated Depreciation	52	23	48	78	109	152	174	275	454	754
CWIP ⓘ	0	0	0	3	4	2	27	22	20	67
Investments ⓘ	190	303	365	356	78	294	520	37	16	67
Inventories	48	56	65	83	69	94	118	131	189	335
Trade Receivables	25	49	67	84	157	140	161	293	422	459
Cash Equivalents	10	2	11	8	67	38	52	58	1,401	223
Others Assets ⓘ	48	90	149	187	186	280	316	363	444	405
Total Assets ⓘ	392	732	1,428	1,481	1,437	1,703	2,113	3,472	6,810	6,862

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	131	200	235	223	271	375	378	292	486	1,065
PBT ⓘ	154	270	312	317	331	394	442	405	431	489
Adjustment ⓘ	20	-1	14	31	44	44	49	140	254	548
Changes in Working Capital ⓘ	-8	-16	-22	-53	-53	5	-30	-176	-99	126
Tax Paid ⓘ	-35	-53	-70	-72	-52	-69	-83	-77	-101	-98
Cash Flow From Investing Activity ⓘ +	-44	-184	-590	-5	123	-323	-320	-982	-1,855	-80
Capex	-24	-50	-25	-37	-146	-26	-120	-841	-129	-155
Net Investments	-21	-135	-38	35	288	-295	-188	-165	-1,731	67
Others ⓘ	0	0	-527	-3	-19	-3	-11	24	5	8
Cash Flow From Financing Activity ⓘ +	-84	-24	363	-221	-335	-82	-45	688	1,380	-881
Net Proceeds from Shares ⓘ	0	0	0	1	0	0	7	2	5	7
Net Proceeds from Borrowing ⓘ	-1	-7	373	-200	-176	0	45	785	1,464	-397
Interest Paid ⓘ	-0	-0	-10	-22	-2	-2	-4	-23	-77	-145
Dividend Paid ⓘ	-83	-17	0	0	-47	-75	-82	-100	0	-100
Others ⓘ	0	0	0	-0	-110	-6	-11	24	-11	-246
Net Cash Flow ⓘ	4	-8	8	-3	60	-30	14	-2	11	104

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	47.68	56.9	41.3	28.96	24.28	24.78	23.33	18.25	16.64	13.81
ROCE (%)	54.56	62.56	35.76	26.54	25.44	27.6	25.29	17.3	12.37	13.59
Asset Turnover Ratio	1.65	1.33	0.79	0.68	0.74	0.79	0.73	0.63	0.41	0.43
PAT to CFO Conversion(x)	0.97	0.81	0.8	0.77	0.91	1.06	0.93	0.78	1.22	2.84
Working Capital Days
Receivable Days	14.60	18.10	24.60	28	40.90	43.60	39.40	46.90	61.70	54.10
Inventory Days	31.20	25.20	25.90	27.50	25.90	24	27.80	25.80	27.70	32.20
Payable Days	113.60	86.20	166.70	207.70	196	155.20	155.60	125.60	165	140.90

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

10.95

18.51

16.93

16.92

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Eris Lifesciences Ltd FAQs

The current trading price of Eris Lifesciences on 24-Jun-2026 16:59 is ₹1,465.5.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 23-Jun-2026 the market cap of Eris Lifesciences stood at ₹20,306.3 Cr

The latest P/E ratio of Eris Lifesciences as of 23-Jun-2026 is 83.21.

The latest P/B ratio of Eris Lifesciences as of 23-Jun-2026 is 6.35.

The 52-week high of Eris Lifesciences is ₹1,887.7 and the 52-week low is ₹1,237.9.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Eris Lifesciences is ₹1,780 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Eris Lifesciences Ltd is a good quality company.

The key valuation ratios of Eris Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Eris Lifesciences Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Eris Lifesciences Ltd

Eris Lifesciences founded by Mr Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroenterology and gynaecology. The company’s focus has been on developing, manufacturing and marketing products which are linked to lifestyle related disorders that are chronic in nature and are treated by superspecialist and specialist doctors. Eris features amongst the Top 30 companies in the Indian Branded Formulations Market.

The company’s core commitment is towards improving health care outcomes and adding value for all its stakeholders including patients, doctors, regulators, employees and business partners. The company is making ongoing efforts to innovate its products to bring the best clinical practices in health care industry to its customers.

The company’s product portfolio is primarily focused on therapeutic areas which are treated by super-specialist and specialist doctors such as Diabetologists, Endocrinologists, Cardiologists, Gastroenterologists, and Neurologists.

Business area of the company

The company develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives. Its focus has been on developing products in the chronic and acute category which are linked to lifestyle related disorders.

History and milestones

2007: Incorporation of the company.
2007: Launched “Eris” division focused on cardiology and diabetes segment.
2008: Launched “Nikkos” division focused on gastroenterology and orthopedics segment.
2009: Launched “Adura” division focused on cardiology and diabetes segment.
2011: Launched “Montana” division focused on gynecology and pediatrics segment.
2012: Launched “Inspira” division focused on cardiology segment.
2014: Launched “Victus” division focused on anti-diabetes segment.
2014: Set up Assam Facility by the company.
2015: Launched “Eris 2” division focused on pain management segment.
2016: Acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited (now, Aprica Pharmaceuticals Private Limited).
2016: Acquired 100.00% of the outstanding equity shares of Aprica Healthcare Private Limited.
2016: Acquired 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited.
2017: Acquired the trademarks ‘UNION’, ‘REUNION’ and ‘BON UNION’.
2017: Eris acquires 40 trademarks from Amay Pharma
2017: Eris acquires Pune based UTH Healthcare.
2018: Eris entered into a distribution agreement with India Medtronic Private Limited.
2019: Eris Lifesciences acquires trademark Zomelis from Novartis AG for $13 mn.
2019: Eris partners with Pharmanutra S.P.A of Italy for Sideral.

Eris Lifesciences Ltd (ERIS)

Eris Lifesciences Ltd (ERIS)

Eris Lifesciences stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Eris Lifesciences - Consolidated

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Eris Lifesciences Ltd FAQs

About Eris Lifesciences Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Eris Lifesciences Ltd (ERIS)

Eris Lifesciences Ltd (ERIS)

Eris Lifesciences stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Eris Lifesciences - Consolidated

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Eris Lifesciences Ltd FAQs

What is the share price of Eris Lifesciences?

What is the market cap of Eris Lifesciences?

What is the P/E ratio of Eris Lifesciences?

What is the P/B ratio of Eris Lifesciences?

What is the 52-week high and low of Eris Lifesciences?

What is the TTM revenue of Eris Lifesciences?

Is Eris Lifesciences Ltd a good quality company?

Is Eris Lifesciences Ltd undervalued or overvalued?

Is Eris Lifesciences Ltd a good buy now?

About Eris Lifesciences Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.